Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold